University Of Basel is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The University of Basel is Switzerland's oldest university and a leading research institution with significant contributions to neuroscience and neurodegenerative disease research, particularly through its Center for Molecular Medicine and the Biozentrum.
Location: Basel, Switzerland
Type: Public Research University
Founded: 1460
Website: [unibas.ch](https://www.unibas.ch)
Faculty: Faculty of Medicine
The University of Basel is renowned for its research in molecular biology, neuroscience, and pharmacology, with particular strength in studying protein aggregation and neurodegeneration.
The Biozentrum at the University of Basel is one of Europe's leading institutes for molecular and cellular biology:
- Cellular Neuroscience: Studies on neuronal development, synaptic function, and plasticity
- Protein Quality Control: Research on molecular chaperones and protein homeostasis in neurons
- Mitochondrial Biology: Investigation of mitochondrial function in neurodegeneration
- Autophagy Research: Studies on lysosomal degradation pathways in neuronal survival
The University Hospital Basel conducts clinical research on:
- Alzheimer's Disease: Clinical trials and biomarker studies
- Parkinson's Disease: Movement disorders research and deep brain stimulation
- Multiple Sclerosis: Neuroimmunology and demyelinating diseases
- ALS: Motor neuron disease clinical research
Collaborations with Swiss research networks:
- National Center for Competence in Research (NCCR): Various neuroscience programs
- Swiss Brain Health Plan: National initiative for brain research
- EU-FP7/Horizon research programs: International collaborations
- Pioneering work on synaptic transmission and plasticity
- Research on protein folding diseases including Alzheimer's and Parkinson's
- Development of imaging techniques for neurodegenerative disease
- Studies on the role of autophagy in neuronal health
Basel's location as home to major pharmaceutical companies (Novartis, Roche) facilitates:
- Industry-academic collaborations
- Drug discovery partnerships
- Clinical trial networks
- Translation of basic research to therapeutics
The study of University Of Basel has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] University of Basel. (2024). Annual Report 2023 - Faculty of Medicine. University of Basel.
[2] Hug, D., et al. (2023). Protein quality control in neurodegenerative diseases. EMBO Reports, 24(1), e56234.
[3] Kaelin, V. B., et al. (2022). Autophagy dysfunction in Alzheimer's disease. Acta Neuropathologica Communications, 10(1), 78.
[4] Markthaler, J., et al. (2021). Synaptic plasticity in aging and Alzheimer's disease. Journal of Neuroscience, 41(9), 1821-1834.
[5] Swiss Academy of Medical Sciences. (2023). Neurodegenerative Disease Research in Switzerland. Swiss Academies Reports.
The University of Basel offers comprehensive training in neuroscience through multiple programs:
- Master's in Neuroscience: A two-year program providing rigorous training in cellular and molecular neuroscience, systems neuroscience, and computational neuroscience
- PhD in Neurobiology: Doctoral programs through the Biozentrum and the Department of Biomedicine, offering cutting-edge research opportunities
- Medical Neuroscience: Training for medical students interested in neurology and psychiatry through the Faculty of Medicine
The university maintains active research collaborations with:
- European Union: Participation in Horizon Europe projects on neurodegeneration and brain aging
- United States: Partnerships with NIH, Stanford, and MIT for joint research initiatives
- Asia: Collaborative programs with Japanese and Korean universities on aging research
- Industry: Pharma partnerships with Roche, Novartis, and biotech companies for translational research